Find your next paid study

Mercator MedSystems, Inc.NCT04862468

~$10 – $8,750

Phase 3

An 18-month, Open-label, Single-arm Safety Extension Study of an age-and Bodyweight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children and Young Adults From 1 to 18 Years of Age With Chronic Kidney Disease and Proteinuria

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a conditi…

Chronic Kidney DiseaseProteinuriaChildren

Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study

This study is being conducted to evaluate how of 30 days of intermittently microdosed psilocybin affects mood, cognition, subjective well-being and structural/…

Psychedelic Microdosing Effects on Mood, Cognition, Subjective Well-being and MRI

Yale UniversityNCT07449351

Observational

Optimizing Lymphatic Pumping for Influenza Vaccine Responses in Vulnerable Populations

The investigators are studying if a specific osteopathic manipulative treatment protocol can improve the immune response (antibody titers) to seasonal influenz…

No Disease or Condition is Being Directly StudiedThe Focus of the Study in Healthy Volunteers

Lake Erie College of Osteopathic MedicineNCT07786467

Observational

Combining At-Home Transcutaneous Auricular Vagus Nerve Stimulation and Computerized Cognitive Training for Neurocognitive Rehabilitation

The purpose of this study is to investigate whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with computerized cognitive training mig…

Psychosocial Well-beingNeurocognitive FunctionCognitive Complaint+1 more

Medical University of South CarolinaNCT07517237

MesotheliomaMalignant Mesothelioma (MM)Early-stage Mesothelioma+3 more

Phase II Evaluation of Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

This is a Phase II study to determine the rate of stabilization or disease improvement from investigational decitabine/cedazuridine (INQOVI) treatment in subje…

National Cancer Institute (NCI)NCT05960773

~$10 – $5,625

Nephrotic SyndromeProteinuriaAutoimmune Disease+2 more

Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

Background: * Membranous nephropathy is associated with damage to the walls of the glomeruli, the small blood vessels in the kidneys that filter waste product…

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT00977977

~$10 – $5,625

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Lepodisiran to Investigate the Effect on Coronary Plaque in Adults With Elevated Lp(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event

Lipoprotein(a), also known as Lp(a), is a protein that carries cholesterol and proteins in your blood. People with high Lp(a) have a higher risk for heart dise…

AtherosclerosisCardiovascular DiseasesLipoprotein(a)

Eli Lilly and CompanyNCT07613294

~$10 – $7,500

Phase 1

A Phase 1, Randomized, Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Doses of Orally Administered LY5625575 in Healthy Participants, Including Japanese and Chinese Populations, and in Participants With Elevated C-Reactive Protein

The main purpose of this study is to evaluate the safety and tolerability of LY5625575 in healthy participants (including Japanese and Chinese) and in particip…

Healthy VolunteersC-Reactive Protein

Eli Lilly and CompanyNCT07801300

~$10 – $7,500

Cognitive DysfunctionLewy Body DiseaseSynucleinopathies+1 more

A Phase 2 Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of Donanemab in Participants With Early Cognitive Decline, at Least One Core Clinical Feature of Dementia With Lewy Bodies, and Confirmation of Alpha-Synuclein and Amyloid Co-pathology

The main purpose of this study is to evaluate whether treatment with donanemab slows the progression of cognitive (how we think, learn, remember, pay attention…

Eli Lilly and CompanyNCT07589595

~$10 – $7,500

Proteinuric Kidney Disease

A Phase 2/3 Adaptive, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of VX-147 in Adult and Pediatric Subjects With APOL1-mediated Proteinuric Kidney Disease

The purpose of this study is to evaluate the efficacy, safety, tolerability, and pharmacokinetics (PK) of VX-147 in adult and pediatric participants with apoli…

Vertex Pharmaceuticals IncorporatedNCT05312879

~$10 – $8,750

Observational

Digital Habit and Neural Indicators of Well-Being

Social media apps are designed to make opening and continuing to use them easy, which may contribute to habitual or unwanted use. This study will test whether …

Social MediaDigital Well-being